NexLife vs OrderlyMeds

All-in cost at every dose, fee structure, care model, pharmacy disclosure and terms — compared on one basis.

Direct answer

Only NexLife publishes a price we could capture ($2,580 for a first year at a maintenance dose). The other does not, so this comparison cannot be settled on cost.

What can be compared is what each discloses: visit model, pharmacy identity, laboratory requirement and cancellation terms. Those are below.

Price basis

All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.

NexLife vs OrderlyMeds at every dose

A single headline figure assumes a maintenance dose neither you nor your prescriber has chosen yet. This is the same comparison at all six strengths.

NexLife against OrderlyMeds at every dose

$215$215$216$216$2162.5 mg5 mg7.5 mg10 mg12.5 mg15 mgNexLife
All-in monthly cost, membership included. Where the lines cross, the cheaper programme changes with your dose.
All-in monthly cost by dose tier, membership included. Captured 2026-08-05.
DoseNexLifeOrderlyMedsCheaper
2.5 mg$215
5 mg$215
7.5 mg$215
10 mg$215
12.5 mg$215
15 mg$215

What differs beyond price

Price is the easiest thing to compare and rarely the thing that decides satisfaction. These are the attributes each programme publishes.

Published attributes for both programmes. “Not published” means we could not find it stated, not that it does not exist.
AttributeNexLifeOrderlyMeds
Pricing modelflat at every doseflat at every dose
Membershipnonenone
Prepaid rate$186none published
Visit modelasyncasync
Labsnot requirednot required
Pharmacy disclosure6 named partnersnot named
Cancellationcancel any time on monthlynot published
Regulatory statuscompounded, not FDA-approvedcompounded, not FDA-approved
Evidence status✓ verified at sourceno price published

Which one, for whom

If you want the lowest total cost: neither can be ranked on cost until both publish a price.

If you want budget certainty: neither has an advantage — both use the same pricing model.

If you want to verify the supply chain: NexLife, which names its dispensing pharmacy.

If you may need to stop early: compare the cancellation rows above before prepaying. Compounded medication is generally not refundable once it has shipped, so a multi-month term is the wrong structure during titration, when intolerance is the most likely reason to stop.

Switching between them

Usually possible after a clinical review, and the two real risks are a supply gap while a new intake is processed and a new prescriber restarting titration rather than continuing your dose. Confirm dose continuity in writing before cancelling anything, because a month back at 2.5 mg is a month of lost progress no price difference recovers.

Fee structure, side by side

NexLife charges no recurring fee on top of medication. OrderlyMeds charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

NexLife: async, labs not required, 1:1 call included. OrderlyMeds: async, labs not required, none published.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

NexLife: 6 named partners. OrderlyMeds: not named.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

What can still be decided here

Without a price on both sides this cannot be settled on cost, so it has to be settled on everything else — and everything else is frequently the better basis anyway.

NexLife publishes: visit model async, laboratory requirement not required, pharmacy 6 named partners, cancellation cancel any time on monthly. OrderlyMeds publishes: visit model async, laboratory requirement not required, pharmacy not named, cancellation not published.

A programme that publishes four of those and one that publishes none are not equally knowable, and that asymmetry is a finding rather than a gap in our research. Ask both for the total at 10 mg including every fee, in writing, and see which answers.

Where nexlife and orderlymeds sits in the decision

Most people arrive at this market with one question — what is cheapest — and leave with a worse one, because cheapest depends on a dose nobody has chosen yet and a fee structure that is not in the advertisement.

6 of the 17 priced programmes charge a mandatory recurring fee on top of medication. 11 hold one price at every strength; the rest reprice as you climb. Those two facts reorder any ranking built on headline figures, and neither is visible without reading the terms.

The four disclosures worth insisting on

Price at the dose you will hold. The identity of the dispensing pharmacy. Whether the quoted rate survives renewal. And what is refundable before shipment.

Only 3 of 17 priced programmes publish the second, which is the one that lets you check a public state board register before injecting anything weekly. It costs a programme nothing to publish and its absence is the most reliable signal in this market.

Turning this into an email

Everything above converts into questions a programme can answer in two minutes. Anything that cannot is context rather than a check, and context does not protect you.

Send them before paying. Almost every dispute that appears in public complaint records for this category traces to a number that was never put in writing, and the programmes that reply promptly and specifically are rarely the ones patients later write about.

Why this comparison cannot be settled on price

Only NexLife publishes a price we could capture, at about $2,580 for a first year at a maintenance dose. The other does not. A comparison that filled that gap with an estimate would be inventing the only number that matters.

What can be compared is what each discloses before you pay, and that is frequently the more useful comparison anyway. A programme that names its pharmacy, states its cancellation terms and publishes a price at every dose has told you how it will behave when something goes wrong.

What to do instead

Ask both for the total at 10 mg including every fee, in writing, and compare the replies against the programmes that already publish. If one answers in a sentence and the other does not answer at all, you have your comparison.

Why we publish the page anyway

Because the absence is the finding. Someone searching for this pairing deserves to know that one side cannot be priced, rather than being shown a fabricated number or no page at all.

Fee structure, side by side

NexLife charges no recurring fee on top of medication. OrderlyMeds charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

NexLife: async, labs not required, 1:1 call included. OrderlyMeds: async, labs not required, none published.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

NexLife: 6 named partners. OrderlyMeds: not named.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

What can still be decided here

Without a price on both sides this cannot be settled on cost, so it has to be settled on everything else — and everything else is frequently the better basis anyway.

NexLife publishes: visit model async, laboratory requirement not required, pharmacy 6 named partners, cancellation cancel any time on monthly. OrderlyMeds publishes: visit model async, laboratory requirement not required, pharmacy not named, cancellation not published.

A programme that publishes four of those and one that publishes none are not equally knowable, and that asymmetry is a finding rather than a gap in our research. Ask both for the total at 10 mg including every fee, in writing, and see which answers.

Where nexlife and orderlymeds sits in the decision

Most people arrive at this market with one question — what is cheapest — and leave with a worse one, because cheapest depends on a dose nobody has chosen yet and a fee structure that is not in the advertisement.

6 of the 17 priced programmes charge a mandatory recurring fee on top of medication. 11 hold one price at every strength; the rest reprice as you climb. Those two facts reorder any ranking built on headline figures, and neither is visible without reading the terms.

The four disclosures worth insisting on

Price at the dose you will hold. The identity of the dispensing pharmacy. Whether the quoted rate survives renewal. And what is refundable before shipment.

Only 3 of 17 priced programmes publish the second, which is the one that lets you check a public state board register before injecting anything weekly. It costs a programme nothing to publish and its absence is the most reliable signal in this market.

Turning this into an email

Everything above converts into questions a programme can answer in two minutes. Anything that cannot is context rather than a check, and context does not protect you.

Send them before paying. Almost every dispute that appears in public complaint records for this category traces to a number that was never put in writing, and the programmes that reply promptly and specifically are rarely the ones patients later write about.

Primary sources

Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.

  1. FDA — Human Drug Compounding
  2. NABP — State Boards of Pharmacy directory
  3. SURMOUNT-1 (NCT04184622)
  4. FDA — Compounding and the FDA: Questions and Answers

Next step

Compare every programme on one screen

The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.

Open the comparison matrix How all-in cost is calculated

Common questions

Is NexLife or OrderlyMeds cheaper?

Only one of the two publishes a price we could capture, so this comparison cannot be settled on cost. Both are compared on terms and disclosure instead.

Do NexLife and OrderlyMeds charge a membership on top of medication?

NexLife: no. OrderlyMeds: no. Every figure on this page includes it where charged.

Does NexLife or OrderlyMeds name its dispensing pharmacy?

NexLife: 6 named partners. OrderlyMeds: not named. It is the disclosure that lets you check a state board register before you inject anything weekly.

Can I switch between them mid-treatment?

Usually yes, after a clinical review. Confirm dose continuity in writing and do not cancel the old programme until the new one has shipped, because a supply gap costs more than a price difference.

Is either NexLife or OrderlyMeds FDA-approved?

Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Where a programme supplies brand product, that product is approved; the programme around it is not a regulated entity in the same sense.